Analyzing Zealand Pharma A/S (ZLDPF) & Its Peers

Zealand Pharma A/S (OTCMKTS:ZLDPF) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Zealand Pharma A/S to related companies based on the strength of its dividends, risk, valuation, institutional ownership, analyst recommendations, earnings and profitability.

Insider & Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 12.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Zealand Pharma A/S and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	8	1	2	2.45
Zealand Pharma A/S Competitors	9782	15052	45294	1571	2.54

As a group, “Biotechnology” companies have a potential upside of 97.70%. Given Zealand Pharma A/S’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Zealand Pharma A/S has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Zealand Pharma A/S and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	$977.29 million	5.73
Zealand Pharma A/S Competitors	$735.22 million	$13.62 million	-10.06

Zealand Pharma A/S has higher revenue and earnings than its competitors. Zealand Pharma A/S is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Zealand Pharma A/S and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	17.56%	16.17%
Zealand Pharma A/S Competitors	-9,054.47%	-198.89%	-30.64%

Volatility & Risk

Zealand Pharma A/S has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S’s competitors have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Summary

Zealand Pharma A/S beats its competitors on 7 of the 13 factors compared.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.